Health · Science · Policy
Drug pricing
Price negotiation, reimbursement and volume-based procurement.
//
This week
- Innovent announces seven products included in 2026 National Reimbursement Drug ListInnovent Biologics announced that seven innovative products, including mazdutide and PECONDLE®, were successfully included in the updated 2026 National Reimbursement Drug List (NRDL), with the updated list taking effect from January 1, 2027. Products newly added to the NRDL include mazdutide (a GCG/GLP-1 dual receptor agonist) for type 2 diabetes, PECONDLE® (picankibart injection) for unspecified indications, TABOSUN®, and Vanflyta®. Products with new indications include TYVYT®, Jaypirca®, and SINTBILO® renewal.FactPrimary source (official or company)StableHealth1 sources · 1 primary · 27 evidence2026-11-14 11:48
- The new version of the medical insurance directory has been released, and the process for innovative drugs to enter the medical insurance system has accelerated.The 2026 National Medical Insurance Drug Catalog and Commercial Insurance Innovative Drug Catalog were released, with the pre-application mechanism making its debut, which shortened the time for innovative drugs to move from approval to inclusion in medical insurance. However, companies still need to face challenges such as hospital access and doctors' prescription habits.SupportedOnly 1 secondary sourceStableHealth1 sources · 21 evidence2026-11-15 10:30
- The IL-23 receptor-targeted oral peptide psoriasis drug, Icotinib tablets, has been included in the drug price list in Japan.On November 13, 2026, the oral peptide psoriasis treatment drug, Icotinib tablets targeting the IL-23 receptor, was included in the Japanese drug pricing list. This is the world's first orally administrable IL-23 receptor-targeting drug, and is expected to expand the options for psoriasis treatment.SupportedOnly 1 secondary sourceStableHealth1 sources · 18 evidence2026-11-12 23:00
- Central State Organs' Desktop Computer Bulk Procurement Order Materializes: 2,680 Units with a Total Amount of 13.096 Million Yuan, All Equipped with Domestic Operating SystemsThe Central Government Organs' 2026 batch centralized procurement project for desktop computers has been awarded, with all 2680 units using domestically developed operating systems. The main winning companies are Zhongguancun and Lianshuo.HypothesisOnly 1 secondary sourceStableHealth1 sources · 2 evidence2026-11-12 11:23
- For the first time, CAR-T anticancer drugs at the million-yuan level have been included in China's basic medical insurance, and patients' out-of-pocket costs have been reduced to within 100,000 yuan.The million-level CAR-T cancer therapy,药明巨诺瑞基奥仑赛注射液 (商品名: 倍诺达®), has been included in China's basic medical insurance catalog for the first time, reducing patient out-of-pocket costs to within 100,000 RMB after reimbursement. The price reduction is attributed to the domestic production of key raw materials, which has significantly lowered manufacturing costs.SupportedOnly 1 secondary sourceStable1 sources · 4 evidence2026-11-14 14:46
5 verified changes this week.
Daily activity
Developing
Signals in this topic
- 01Innovent announces seven products included in 2026 National Reimbursement Drug ListInnovent Biologics announced that seven innovative products, including mazdutide and PECONDLE®, were successfully included in the updated 2026 National Reimbursement Drug List (NRDL), with the updated list taking effect from January 1, 2027. Products newly added to the NRDL include mazdutide (a GCG/GLP-1 dual receptor agonist) for type 2 diabetes, PECONDLE® (picankibart injection) for unspecified indications, TABOSUN®, and Vanflyta®. Products with new indications include TYVYT®, Jaypirca®, and SINTBILO® renewal.New primary claim2026-11-14 11:48
- 02The IL-23 receptor-targeted oral peptide psoriasis drug, Icotinib tablets, has been included in the drug price list in Japan.On November 13, 2026, the oral peptide psoriasis treatment drug, Icotinib tablets targeting the IL-23 receptor, was included in the Japanese drug pricing list. This is the world's first orally administrable IL-23 receptor-targeting drug, and is expected to expand the options for psoriasis treatment.New primary claim2026-11-12 23:00
- 03Hagens Berman files securities class action against CVRx following DOJ CID and revenue guidance cutA federal class action lawsuit was filed against CVRx, Inc. after the company disclosed a U.S. Department of Justice Civil Investigative Demand, a significant revenue guidance cut, sales force deterioration, and a collapse in Medicare Advantage approval rates. The complaint alleges CVRx misled investors about its commercial sales force and reimbursement rates.Filing change2026-11-17 00:45
- 04Central State Organs' Desktop Computer Bulk Procurement Order Materializes: 2,680 Units with a Total Amount of 13.096 Million Yuan, All Equipped with Domestic Operating SystemsThe Central Government Organs' 2026 batch centralized procurement project for desktop computers has been awarded, with all 2680 units using domestically developed operating systems. The main winning companies are Zhongguancun and Lianshuo.Policy change2026-11-12 11:23
- 05The new version of the medical insurance directory has been released, and the process for innovative drugs to enter the medical insurance system has accelerated.The 2026 National Medical Insurance Drug Catalog and Commercial Insurance Innovative Drug Catalog were released, with the pre-application mechanism making its debut, which shortened the time for innovative drugs to move from approval to inclusion in medical insurance. However, companies still need to face challenges such as hospital access and doctors' prescription habits.Policy change2026-11-15 10:30
- 06For the first time, CAR-T anticancer drugs at the million-yuan level have been included in China's basic medical insurance, and patients' out-of-pocket costs have been reduced to within 100,000 yuan.The million-level CAR-T cancer therapy,药明巨诺瑞基奥仑赛注射液 (商品名: 倍诺达®), has been included in China's basic medical insurance catalog for the first time, reducing patient out-of-pocket costs to within 100,000 RMB after reimbursement. The price reduction is attributed to the domestic production of key raw materials, which has significantly lowered manufacturing costs.New primary claim2026-11-14 14:46